Publicado 18/10/2019 07:55
- Comunicado -

EVENITY (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women a

CONTACT: UCB, BrusselsScott Fleming, Bone Communications, UCB, T+44-7702777378, scott.fleming@ucb.comFrance Nivelle, Global Communications,UCB, T +32-2-559-9178, france.nivelle@ucb.comLaurent Schots, MediaRelations, UCB, T+32-2-559-92-64, laurent.schots@ucb.comAntje Witte,Investor Relations, UCB, T +32-2-559-94-14, antje.witte@ucb.comIsabelleGhellynck, Investor Relations, UCB, T+32-2-559-9588,isabelle.ghellynck@ucb.com Contact: Amgen, Thousand OaksKelley Davenport,202-585-9637 (media)Kristen Davis, 805-447-3008 (media) Arvind Sood,805-447-1060 (investors)

Contenido patrocinado